-0.83% for AbbVie stock as shares remain under key resistance levels

Traders Union
All News
Companies
AbbVie slips 0.83% today

Highlights

ABBV trades below major moving averages, reflecting continued seller control across short-, medium-, and long-term timeframes.
Indicators suggest weak momentum and mild oversold conditions, but no clear evidence of a bullish reversal emerging.
Price is expected to consolidate between $205 and $215 this week, with further downside risk if support at $205 fails.

ABBV is trading at $209.37, which is below the MA-20 ($219.63), MA-50 ($221.73), and MA-200 ($215.72) on D1, reflecting persistent seller pressure across short-, medium-, and long-term horizons. The Ichimoku Kijun on D1 stands at $219.46, currently acting as immediate resistance above the current price. Near-term support is seen at the MA-5/MA-10 cluster near $209.86, while key support lies at the MA-200 ($215.72); immediate resistance is defined by the Ichimoku Kijun ($219.46) with key resistance at the MA-50 ($221.73).

Momentum indicators on D1 show that MACD signals ongoing downside pressure, while ADX at 16.72 points to a weak, non-trending environment. RSI at 37.53, CCI at –63.34, and Stoch RSI in neutral territory indicate a mild oversold condition, but not an extreme. The BBP D1 value of 0.51 places buyers in control of intraday momentum, even as oscillators and trend signals remain mixed. ABBV is trading at $209.37, up from last week’s close at $205.07, a gain of 2.09%. The price is positioned in the upper part of the weekly range, and volatility has reached 5.72%. The week reflects a recovery from the weekly low, with momentum and oscillator divergences indicating uncertain follow-through.

For the coming week, the expected range is $205 to $215, using weekly volatility and the forecasted resistance cluster as boundaries. With no “Buy” or “Strong Buy” signals among RSI W1, ADX W1, MACD W1, and MA-50 W1, the probability of a price increase is very low (less than 20%), making further downside more likely. The baseline scenario is for ABBV to consolidate between $205 and $215, holding above recent weekly lows but capped by overhead resistance. A bullish scenario would require a decisive break above $215 to open room toward $220. Conversely, a bearish move below $205 could target supports closer to $201.80, with the price range set well above the 52-week low of $164.39 but still well below the annual high of $244.81.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that AbbVie shares were experiencing persistent downside pressure, with analysts adopting a cautious, sideways outlook. This article revisits those conditions to address any evolving trends, highlighting the importance for investors to monitor for a decisive breakout that could signal AbbVie's next directional move.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.